1652.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 14:47):

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China...

Stats
今日成交量	331 000
平均成交量	135 912
市值	652.52M
EPS	HKD0 ( 2023-08-29 )
下一个收益日期	( HKD0 ) 2024-05-28
Last Dividend	HKD0.00420 ( 2022-06-07 )
Next Dividend	HKD0 ( N/A )
P/E	-17.60
ATR14	HKD0 (0.00%)

Fusen Pharmaceutical 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Fusen Pharmaceutical 财务报表

Annual	2023
营收:	HKD565.61M
毛利润:	HKD299.51M (52.95 %)
EPS:	HKD-0.0500

FY	2023
营收:	HKD565.61M
毛利润:	HKD299.51M (52.95 %)
EPS:	HKD-0.0500

FY	2022
营收:	HKD491.76M
毛利润:	HKD225.02M (45.76 %)
EPS:	HKD-0.0458

FY	2021
营收:	HKD385.66M
毛利润:	HKD211.13M (54.75 %)
EPS:	HKD0.0210

Financial Reports:

No articles found.

Fusen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Fusen Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.583 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	HKD0.00620	2018-09-13
Last Dividend	HKD0.00420	2022-06-07
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.0436	--
Avg. Dividend % Per Year	0.00%	--
Score	1.1	--
Div. Sustainability Score	1.583
Div.Growth Potential Score	0
Div. Directional Score	0.0742	--

Next Divdend (Est)
(2024-08-30)

HKD0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

1.10

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2611.HK	Ex Dividend Junior	2023-06-09	Annually	0.00%
1398.HK	Ex Dividend Junior	2023-07-06	Annually	0.00%
0460.HK	Ex Dividend Junior	2023-06-06	Annually	0.00%
6837.HK	No Dividend Player	2023-06-30	Annually	0.00%
1955.HK	Ex Dividend Junior	2023-09-13	Annually	0.00%
0984.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%
0088.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
3328.HK	Ex Dividend Junior	2023-07-04	Annually	0.00%
1543.HK	Ex Dividend Junior	2023-06-30	Annually	0.00%
0586.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0641	1.500	-1.283	-1.924	[0 - 0.5]
returnOnAssetsTTM	-0.0270	1.200	-0.900	-1.080	[0 - 0.3]
returnOnEquityTTM	-0.0612	1.500	-1.791	-2.69	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.853	0.800	-0.735	-0.588	[1 - 3]
quickRatioTTM	0.329	0.800	-2.77	-2.22	[0.8 - 2.5]
cashRatioTTM	0.0524	1.500	-0.820	-1.230	[0.2 - 2]
debtRatioTTM	0.255	-1.500	5.75	-8.62	[0 - 0.6]
interestCoverageTTM	6.34	1.000	8.76	8.76	[3 - 30]
operatingCashFlowPerShareTTM	-0.0619	2.00	-0.0206	-0.0412	[0 - 30]
freeCashFlowPerShareTTM	-0.118	2.00	-0.0590	-0.118	[0 - 20]
debtEquityRatioTTM	0.609	-1.500	7.57	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.530	1.000	4.51	4.51	[0.2 - 0.8]
operatingProfitMarginTTM	0.0379	1.000	-1.241	-1.241	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.135	1.000	-1.862	-1.862	[0.2 - 2]
assetTurnoverTTM	0.421	0.800	-0.527	-0.422	[0.5 - 2]
Total Score				1.583

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-16.77	1.000	-1.795	0	[1 - 100]
returnOnEquityTTM	-0.0612	2.50	-1.151	-2.69	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.118	2.00	-0.0393	-0.118	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0619	2.00	-0.0206	-0.0412	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0819	1.000	-4.55	0	[0.1 - 0.5]
Total Score				-1.434

Fusen Pharmaceutical

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.